IDRSF (Idorsia) Additional Paid-In Capital : $2,571.3 Mil(As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Idorsia Additional Paid-In Capital?

Idorsia's quarterly additional paid-in capital declined from Mar. 2024 ($2,428.6 Mil) to Jun. 2024 ($2,417.7 Mil) but then increased from Jun. 2024 ($2,417.7 Mil) to Sep. 2024 ($2,571.3 Mil).

Idorsia's annual additional paid-in capital increased from Dec. 2021 ($2,280.4 Mil) to Dec. 2022 ($2,283.0 Mil) and increased from Dec. 2022 ($2,283.0 Mil) to Dec. 2023 ($2,492.6 Mil).

Idorsia Additional Paid-In Capital Historical Data

The historical data trend for Idorsia's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Idorsia Additional Paid-In Capital Chart

Idorsia Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

1,102.87

2,209.30

2,280.39

2,283.02

2,492.62

Idorsia Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Additional Paid-In Capital	Get a 7-Day Free Trial															2,392.13	2,492.62	2,428.58	2,417.68	2,571.33

Idorsia Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Idorsia Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Idorsia's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Idorsia Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Idorsia Ltd (OTCPK:IDRSF) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

IDIAz:UK 0RQE:UK IDIA:Switzerland

Address

Hegenheimermattweg 91, Allschwil, CHE, 4123

Website

https://www.idorsia.com

Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide innovative therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.